Astellas Pharma Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Naoki Okamura
- Full Time Employees
- 14,099
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 2-5-1, Nihonbashi-Honcho Tokyo TY Japan 103-8411
- IPO Date
- Dec 29, 2009
- CIK
- 0001376684
- Website
- astellas.com
- Similar Companies
- Business
- Astellas Pharma Inc. (ALPMY) develops, manufactures, markets, and distributes pharmaceutical products worldwide, with a focus on oncology, rare diseases, immunology, nephrology, urology, ophthalmology, and women's health; core brands include XTANDI and PADCEV for prostate and urothelial cancers, XOSPATA for acute myeloid leukemia, VYLOY (zolbetuximab) for gastric cancer, VEOZAH (fezolinetant) for menopause symptoms, IZERVAY (avacincaptad pegol) for geographic atrophy, EVRENZO for anemia in chronic kidney disease, BETANIS/Myrabetriq/BETMIGA for overactive bladder, and PROGRAF/Advagraf immunosuppressants for transplantation. Headquartered in Tokyo, Japan, and founded in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, the company operates in over 70 countries across Japan, the Americas, Europe, Middle East, Africa, and Asia-Oceania, employing more than 13,500 people and reporting fiscal 2024 revenue of ¥1,912.3 billion ($12.58 billion). Recent developments include a May 2025 licensing deal with Evopoint Biosciences for a CLDN18.2-targeting antibody-drug conjugate worth up to $1.34 billion, a 2024 TCR-T cell therapy collaboration with Poseida Therapeutics, a $50 million option agreement with AviadoBio in October 2024 for a frontotemporal dementia gene therapy, strategic investments in later-stage assets amid pipeline reprioritization, and ongoing partnerships such as with Vivtex Corporation for oral formulation technology and Roche Diabetes Care Japan for diabetes management solutions.
Company News
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Kyowa Kirin (OTCMKTS:KYKOF) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Analysis
New Strong Sell Stocks for August 19th
Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors
New Strong Sell Stocks for August 6th
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Is Astellas Pharma (ALPMY) Stock Undervalued Right Now?
Is Astellas Pharma (ALPMY) a Great Value Stock Right Now?
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Astellas Targets ¥4.3 Trillion Profit Push As Xtandi Pressure Builds
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
Astellas collaborates with Vir to develop its experimental prostate cancer drug